abil
rescu
infecti
recombin
negativestrand
rna
viru
cdna
clone
led
new
opportun
measur
viral
replic
viral
express
report
gene
studi
enhanc
green
fluoresc
protein
egfp
gene
insert
human
parainfluenza
viru
type
antigenom
recombin
infecti
viru
rescu
maximum
egfp
express
level
measur
fluoresc
seen
day
comparison
threeday
viral
express
egfp
fluoresc
assay
sevenday
neutral
red
assay
base
complet
cell
destruct
viru
infect
cell
yield
valu
respect
threeday
endpoint
egfpbas
antivir
assay
sevenday
endpoint
neutral
red
base
antivir
assay
run
parallel
establish
antivir
sensit
profil
compound
base
select
index
si
valu
use
si
threshold
egfpbas
antivir
assay
sensit
specif
thu
use
egfpbas
antivir
assay
test
potenti
antivir
compound
highthroughput
format
may
justifi
discoveri
new
antivir
drug
usual
requir
success
test
vitro
prior
develop
measur
efficaci
drug
cellbas
antivir
assay
involv
colorimetr
luminesc
detect
system
use
colorimetr
assay
often
measur
absorpt
neutral
red
bromid
mtt
taken
intact
cell
cell
indic
cell
health
neutral
red
measur
membran
integr
absorb
lysosom
mtt
insid
cell
reduc
yellow
tetrazolium
salt
waterinsolubl
purpl
formazan
crystal
mitochondri
reductas
barnard
et
al
finter
watanab
et
al
time
consum
labor
intens
natur
method
proven
drawback
smee
et
al
altern
type
detect
method
celltiterglo
luminesc
cell
viabil
assay
promega
madison
wi
measur
atp
gener
intact
cell
noah
et
al
assay
claim
sensit
less
time
consum
less
labor
intens
even
though
luminesc
assay
may
solv
disadvantag
colorimetr
assay
sever
issu
aris
also
common
colorimetr
assay
well
major
problem
cell
viabil
assay
design
detect
cell
death
differenti
drug
toxic
viral
cytopath
effect
cpe
conduct
parallel
drug
toxic
assay
two
factor
mathemat
separ
although
assum
differ
measur
assay
due
drug
toxic
cpe
independ
assumpt
ignor
possibl
posit
neg
compound
effect
potenti
interact
drug
viru
second
problem
inabl
virus
produc
detect
amount
cpe
andor
long
incub
time
need
reach
complet
cell
monolay
destruct
often
requir
get
accuraci
dye
uptak
assay
colorimetr
luminesc
antivir
assay
effect
reliabl
complet
cell
destruct
necessari
obtain
signific
signaltobackground
ratio
viral
incub
time
may
extend
day
virus
problemat
cell
control
may
surviv
long
third
problem
detect
syncytia
initi
caus
cell
destruct
earli
syncytia
format
problemat
even
though
viral
cpe
visual
within
day
syncytia
absorb
similar
amount
neutral
red
mtt
compar
uninfect
cell
smee
et
al
therefor
necessari
complet
destruct
syncytia
dye
uptak
assay
differenti
uninfect
cell
cell
impact
syncyti
format
therefor
detect
system
directli
measur
chang
cpe
independ
drug
toxic
shorter
amount
time
would
prefer
one
strategi
enhanc
sensit
decreas
incub
time
assay
would
construct
recombin
viru
express
report
gene
exampl
gene
fluoresc
protein
could
clone
directli
viral
genom
would
express
proport
viru
replic
allow
direct
cpe
measur
independ
drug
toxic
done
antivir
compound
screen
purpos
insert
gene
green
fluoresc
protein
genom
ebolaviru
cytomegaloviru
marschal
et
al
towner
et
al
thu
syncyti
form
virus
human
parainfluenza
viru
type
similar
approach
would
use
reduc
time
need
complet
antivir
assay
two
recombin
virus
construct
express
green
fluoresc
protein
extens
studi
valid
use
cellbas
antivir
assay
one
viru
strain
js
use
follow
infect
recombin
viru
lung
epithelium
zhang
et
al
second
viru
strain
use
screen
librari
potenti
antivir
compound
yet
specif
detail
replic
differ
recombin
viru
express
fluoresc
protein
compar
wildtyp
strain
discuss
mao
et
al
paper
recombin
viru
express
enhanc
green
fluoresc
protein
egfp
rescu
evalu
use
antivir
assay
compar
sidebysid
wildtyp
wt
recombin
strain
slight
differ
virul
viru
wt
viru
cell
cultur
may
valid
possibl
substitut
wt
viru
primari
highthroughput
antivir
assay
human
cervic
carcinoma
cell
hela
obtain
american
type
cultur
collect
atcc
manassa
va
maintain
co
minim
essenti
medium
mem
hyclon
laboratori
logan
ut
supplement
fetal
bovin
serum
fb
hyclon
laboratori
mm
nonessenti
amino
acid
neaa
invitrogen
carlsbad
ca
mm
sodium
pyruv
invitrogen
embryon
african
green
monkey
kidney
cell
obtain
atcc
maintain
co
mem
supplement
fb
recombin
vaccinia
viru
express
bacteriophag
rna
polymeras
gener
provid
dr
bernard
moss
propag
hela
cell
fuerst
et
al
wt
isol
j
bouvin
hosp
st
justin
montreal
canada
propag
cell
antivir
assay
cell
incub
mem
supplement
fb
gentamicin
sigma
chemic
compani
st
loui
mo
hydroxymethyl
obtain
sigma
remaind
antivir
compound
includ
hydroxymethyl
ribavirin
imidazo
adenosin
obtain
repositori
niaid
antivir
substanc
program
nih
also
obtain
repositori
nucleosid
analog
compound
submit
use
permiss
dr
michael
otto
pharmasset
inc
fusion
protein
also
obtain
repositori
submit
use
permiss
dr
fang
fang
nexbio
inc
malakhov
et
al
three
overlap
complementari
dna
cdna
strand
encompass
viral
base
gener
rna
isol
wt
strain
infect
forward
revers
primer
deriv
consensu
sequenc
three
known
strain
js
gpv
galinski
ohsawa
et
al
stoke
et
al
gener
cdna
segment
forward
primer
contain
aatii
paci
restrict
site
bold
promot
underlin
revers
primer
use
gener
cdna
segment
forward
primer
contain
natur
bsteii
restrict
site
bold
revers
primer
use
gener
cdna
segment
forward
primer
revers
primer
contain
mutat
draiii
restrict
site
bold
two
mutat
c
g
underlin
use
cdna
segment
insert
smai
site
new
england
biolab
neb
ipswich
clone
sequenc
direct
assur
accuraci
sphi
site
cdna
segment
destroy
mutat
g
viral
base
posit
use
quikchang
xl
sitedirect
mutagenesi
stratagen
la
jolla
ca
kit
forward
primer
revers
primer
confirm
sequenc
end
wt
genom
poli
tail
ad
end
isol
wt
rna
use
poli
tail
kit
ambion
austin
tx
tail
rna
amplifi
rtpcr
use
nucleotid
nt
poli
oligonucleotid
forward
primer
revers
primer
sequenc
end
wt
genom
smart
race
cdna
amplif
kit
clontech
use
wt
specif
primer
use
prime
cdna
synthesi
also
use
pcr
amplif
step
forward
primer
pcr
product
reaction
sequenc
complet
wt
genom
genbank
access
two
oligonucleotid
gener
contain
base
pair
overlap
gagggtga
taggtacc
oligonucleotid
anneal
togeth
extend
use
sequenas
version
dna
polymeras
usb
corpor
cleveland
ohio
fragment
insert
smai
site
name
complet
segment
contain
paci
bsteii
draiii
smai
kpni
site
bold
termin
sequenc
underlin
two
vaccinia
viru
termin
sequenc
flank
end
italic
second
set
oligonucleotid
anneal
extend
insert
manner
tcccttagccatccgagtggacgacgtcctccttcggatgcccaggtcggacc
complet
segment
contain
kpni
draiii
restrict
site
bold
antigenom
hepat
delta
viru
ribozym
underlin
perrotta
viral
base
italic
digest
draiii
kpni
produc
base
pair
bp
segment
insert
site
renam
destroy
nativ
sphi
site
renam
adapt
use
oligonucleotid
insert
draiii
bsteii
site
encod
sphi
site
bold
renam
next
cdna
segment
digest
bsteii
sphi
insert
site
renam
cdna
segment
digest
paci
bsteii
insert
site
renam
final
cdna
segment
digest
draiii
sphi
insert
site
renam
cdna
segment
digest
aatii
bsteii
insert
site
neb
name
open
read
frame
egfp
amplifi
pcr
use
pegfp
clontech
mountain
view
ca
templat
forward
revers
attaaccggcgctcagttgg
primer
primer
contain
drdi
restrict
site
bold
end
revers
primer
also
includ
wt
gene
end
intercistron
gene
start
signal
underlin
bp
band
purifi
insert
smai
site
renam
digest
drdi
produc
bp
band
insert
site
name
genom
cdna
segment
contain
egfp
digest
paci
bsteii
insert
site
name
final
cdna
segment
digest
draiii
sphi
insert
site
renam
three
pcr
product
encompass
nucleocapsid
protein
np
phosphoprotein
p
larg
protein
l
insert
smai
site
name
follow
three
set
forward
revers
primer
use
np
p
l
start
codon
bold
wt
accessori
c
protein
locat
p
forward
primer
mutat
c
underlin
silenc
express
digest
sali
kpni
kb
kb
kb
band
respect
insert
site
ptnt
promega
name
ptntnp
ptntp
ptntl
hela
cell
seed
plate
infect
pfu
multipl
infect
moi
hour
viru
medium
remov
replac
optimem
invitrogen
contain
mm
neaa
three
support
plasmid
ptntnp
ptntp
ptntl
cotransfect
along
either
use
lipofectamin
invitrogen
hour
mem
supplement
fb
mm
neaa
mm
sodium
pyruv
cytosin
arac
sigma
ad
transfect
incub
hour
transfect
cell
scrape
supernat
frozen
rescu
transfect
transfect
virus
amplifi
cell
supplement
arac
day
cell
scrape
supernat
frozen
viru
purifi
pick
agaros
plug
isol
plaqu
cell
absenc
arac
plug
place
mem
froze
media
contain
plug
isol
viru
use
infect
cell
amplifi
viru
day
purif
amplif
step
repeat
two
time
wt
virus
amplifi
cell
day
infect
cell
scrape
supernat
frozen
use
test
sequenc
end
genom
rna
isol
infect
repeat
use
smart
race
cdna
amplif
kit
confirm
draiii
genet
marker
plaqu
assaydupl
dilut
wt
use
infect
cell
quadrupl
viru
absorb
hour
viru
remov
replac
overlay
seaplaqu
lowmelt
agaros
isc
bioexpress
kaysvil
ut
supplement
mem
sodium
bicarbon
incub
day
cell
fix
formaldehyd
hour
room
temperatur
formaldehyd
agaros
overlay
remov
crystal
violet
ad
minut
remov
dye
one
rins
phosphat
buffer
salin
pb
stain
plaqu
count
viral
titer
compar
statist
analyz
unpair
twotail
student
ttest
use
microsoft
offic
excel
softwar
redmond
wa
addit
plaqu
produc
also
photograph
use
eclips
microscop
nikon
melvil
ny
coolsnap
digit
camera
rs
imag
softwar
version
roper
scientif
photometr
tucson
az
fluoresc
photograph
taken
equip
except
uv
light
fluoresc
filter
combin
use
incorpor
excit
wavelength
nm
emiss
filter
wavelength
greater
nm
onestep
growth
curvedupl
plate
seed
cell
infect
pfu
wt
virus
separ
moi
viru
absorb
hour
viru
remov
replac
fresh
mem
supplement
fb
incub
individu
cell
scrape
supernat
harvest
everi
six
hour
start
time
viru
exposur
frozen
time
viru
ad
immedi
remov
replac
fresh
medium
time
point
viru
plaqu
titer
quadrupl
follow
method
describ
growth
curv
compar
two
curv
individu
statist
analyz
analysi
varianc
anova
use
microsoft
offic
excel
softwar
cytopath
effect
assayninetysixwel
plate
seed
cell
infect
pfu
either
wt
viru
duplic
moi
quadrupl
well
plate
incub
day
includ
day
infect
cell
stain
neutral
red
nr
hour
wash
pb
nr
extract
ethanol
citrat
buffer
min
rock
room
temperatur
absorb
nm
wavelength
read
opsi
mr
spectrophotomet
revel
quicklink
softwar
version
dynex
technolog
chantilli
va
two
curv
compar
statist
analyz
anova
plate
seed
cell
infect
pfu
wt
virus
separ
duplic
moi
specif
time
point
hour
uninfect
infect
cell
harvest
use
cell
direct
resuspens
lysi
buffer
invitrogen
lysat
use
templat
two
differ
revers
transcriptas
rt
reaction
one
reaction
use
primer
specif
genom
reaction
use
oligo
dt
primer
invitrogen
primer
use
pcr
amplifi
cdna
product
rt
reaction
includ
fam
genom
replic
fam
l
gene
transcript
platinum
quantit
pcr
supermixudg
invitrogen
nm
forward
revers
lux
primer
invitorgen
th
rt
reaction
mix
ad
triplic
hardshel
skirt
pcr
plate
biorad
laboratori
hercul
ca
reaction
run
dna
engin
opticon
realtim
pcr
detect
system
mj
research
waltham
opticon
monitor
softwar
version
biorad
laboratori
use
calcul
rel
express
differ
deltac
time
point
viru
use
hour
viru
calibr
pfaffl
assay
two
curv
compar
statist
analyz
anova
antivir
cpe
assay
use
evalu
antivir
sensit
profil
wt
virus
barnard
et
al
cavanaugh
et
al
briefli
three
compound
ribavirin
posit
control
plate
four
tenfold
dilut
five
replic
plate
seed
cell
use
start
concentr
respect
two
five
replic
toxic
control
viru
ad
three
replic
infect
pfu
either
wt
viru
moi
plate
incub
day
cell
plate
stain
nr
follow
method
describ
assay
done
three
time
fifti
percent
effect
concentr
ec
calcul
linear
regress
use
percent
untreat
uninfect
cell
untreat
infect
viru
control
ec
valu
compar
statist
analyz
unpair
twotail
student
ttest
ninetysixwel
plate
seed
cell
infect
pfu
duplic
moi
quadrupl
four
tenfold
dilut
viru
plate
cultur
incub
day
day
includ
day
infect
medium
remov
cell
cell
wash
pb
fresh
pb
ad
day
infect
viru
ad
immedi
remov
cell
wash
pb
egfp
fluoresc
measur
fmax
fluoromet
use
nm
excit
nm
emiss
filter
record
softmax
pro
softwar
version
molecular
devic
union
citi
ca
duplic
plate
seed
cell
plate
well
infect
pfu
moi
well
left
uninfect
cell
control
well
left
unseed
nocel
background
control
plate
incub
day
incub
uninfect
infect
cell
unseed
well
wash
pb
replac
fresh
pb
fluoresc
measur
use
fmax
fluoromet
tradit
nrbase
assay
vybrant
mtt
cell
prolifer
assay
invitrogen
done
follow
plate
format
except
cell
treat
result
measur
complet
infect
cell
lysi
day
cell
nr
assay
stain
follow
procedur
describ
earlier
manufactur
quick
protocol
follow
stain
cell
vybrant
mtt
assay
absorb
valu
cell
treat
mtt
measur
use
nm
wavelength
opsi
mr
spectrophotomet
revel
quicklink
softwar
celltiterglo
luminesc
cell
viabil
assay
promega
also
perform
use
format
except
cell
seed
white
half
area
plate
clear
bottom
therefor
plate
volum
reduc
celltiterglo
reagent
reduc
otherwis
follow
manufactur
protocol
luminesc
measur
use
centro
lb
luminomet
record
mikrowin
softwar
version
berthold
technolog
oak
ridg
tn
six
plate
seed
cell
evalu
nr
egfp
assay
parallel
format
use
allow
seven
compound
test
per
plate
compound
plate
use
four
tenfold
dilut
triplic
start
concentr
ml
ribavirin
posit
control
ribamidin
adenosin
selenazofurin
eicar
compound
reconstitut
dmso
dilut
work
concentr
dmso
less
elimin
cell
toxic
due
dmso
two
replic
infect
pfu
moi
remain
replic
serv
toxic
control
viru
ad
three
plate
incub
day
toxic
cell
control
cell
stain
nr
follow
procedur
describ
earlier
nr
fluoresc
measur
fmax
fluoromet
use
nm
excit
nm
emiss
filter
untreat
viru
control
treat
infect
cell
wash
pb
fresh
pb
ad
fluoresc
measur
fmax
fluoromet
use
nm
excit
nm
emiss
filter
three
plate
assay
use
tradit
colorimetr
nr
assay
incub
day
cell
stain
nr
follow
procedur
describ
earlier
nr
assay
ec
cell
inhibitori
concentr
ic
calcul
linear
regress
percent
untreat
uninfect
cell
untreat
infect
viru
control
egfp
assay
ec
valu
calcul
linear
regress
use
percent
untreat
infect
viru
control
ic
valu
also
calcul
linear
regress
use
percent
untreat
uninfect
cell
control
ec
ic
valu
compound
assay
compar
statist
analyz
unpair
twotail
student
ttest
select
index
si
calcul
compound
assay
use
formula
si
mean
ic
mean
ec
compound
sort
posit
neg
si
categori
combin
nr
egfp
assay
use
nr
assay
gold
standard
sensit
true
posit
true
positivesfals
neg
specif
true
neg
true
negativesfals
posit
calcul
drdi
restrict
site
found
n
gene
start
signal
start
codon
wt
genom
use
facilit
insert
egfp
gene
therefor
forward
revers
primer
use
amplifi
egfp
open
read
frame
design
contain
drdi
restrict
site
end
wt
gene
end
intercistron
gene
start
signal
also
encod
onto
revers
primer
insert
egfp
gene
would
recogn
addit
wt
gene
fig
rule
six
follow
gener
bp
egfp
gene
segment
rule
suggest
viral
replic
effici
viral
genom
length
factor
six
like
due
singl
nucleocapsid
protein
bind
six
genom
ribonucleotid
calain
roux
durbin
et
al
construct
recombin
express
egfp
presenc
three
g
ribonucleotid
equal
separ
ribonucleotid
start
ribonucleotid
end
antigenom
manipul
locat
repres
one
complet
turn
helic
structur
nucleocapsid
encas
rna
genom
thought
coregul
viral
replic
perhap
assembl
bind
viral
polymerasephosphoprotein
complex
nucleocapsid
tapparel
et
al
egfp
forward
primer
interrupt
natur
pattern
problem
solv
ad
three
g
residu
forward
primer
posit
addit
egfp
gene
segment
antigenom
cdna
segment
clone
plasmid
circumv
multipl
drdi
restrict
site
locat
plasmid
result
cdna
segment
encod
gene
egfp
clone
plasmid
alreadi
contain
cdna
segment
final
addit
cdna
segment
construct
result
complet
infecti
recombin
viru
express
egfp
gene
demonstr
success
rescu
isol
two
strain
one
one
without
egfp
gene
insert
sequenc
surround
three
genet
marker
align
compar
wt
viru
isol
fig
rna
isol
wt
infect
amplifi
rtpcr
sequenc
gener
race
rtpcr
contain
draiii
restrict
site
confirm
atoc
ttog
mutat
two
mutat
creat
uniqu
draiii
restrict
site
present
recombin
virus
allow
insert
final
cdna
segment
complet
recombin
virus
third
genet
marker
also
confirm
align
sequenc
gener
end
l
gene
three
virus
atog
mutat
elimin
one
two
natur
sphi
restrict
site
locat
l
gene
portion
wt
viru
second
sphi
restrict
site
use
insert
cdna
segment
pcr
product
also
digest
sphi
separ
agaros
gel
show
wt
digest
presenc
sphi
two
recombin
virus
fig
plaqu
form
stain
crystal
violet
analyz
bright
field
microscopi
viral
induc
syncytia
absorb
crystal
violet
compar
surround
uninfect
cell
fig
syncytia
plaqu
visual
fluoresc
microscopi
high
concentr
green
fluoresc
fig
hand
plaqu
form
wt
produc
fluoresc
data
shown
result
demonstr
direct
correl
viral
growth
syncytia
format
egfp
express
infecti
viru
present
stock
three
virus
plaqu
titer
mean
standard
deviat
duplic
assay
found
pfuml
wt
pfuml
pfuml
infecti
viru
titer
significantli
differ
compar
wt
p
wherea
significantli
lower
compar
wt
p
addit
egfp
gene
genom
appear
attenu
compar
either
wt
recombin
strain
howev
process
creat
rescu
recombin
viru
andor
presenc
three
genet
marker
caus
attenu
signific
reduct
viru
titer
seen
subsequ
experi
volum
viru
inoculum
adjust
equal
pfu
ad
addit
replic
kinet
three
virus
wt
rhpivegfp
measur
confirm
attenu
compar
wildtyp
recombin
virus
growth
curv
wt
similar
signific
differ
p
fig
howev
growth
curv
significantli
delay
compar
growth
curv
wt
p
initi
stage
infect
attenu
growth
compar
wildtyp
recombin
virus
seen
yet
appear
replic
viru
may
recov
amplifi
similar
level
compar
two
virus
later
stage
replic
result
confirm
addit
addit
gene
genom
may
caus
attenu
cpe
produc
wt
virus
infect
cell
monitor
day
measur
nr
uptak
complet
infect
cell
lysi
occur
verifi
microscop
examin
complet
cell
lysi
induc
virus
occur
time
day
signific
differ
either
curv
detect
p
fig
result
contradict
previou
result
show
attenu
replic
viru
result
support
idea
abl
recov
replic
wt
standard
determin
addit
gene
may
contribut
attenu
seen
onset
infect
qrtpcr
assay
done
measur
genom
replic
l
gene
transcript
specif
primer
anneal
intergen
sequenc
fusion
hemagglutininneuraminidas
gene
viral
negativesens
rna
allow
bind
viral
genom
rna
rather
viral
mrna
viral
positivesens
antigenom
rna
use
primer
rt
reaction
oligo
dt
primer
use
prime
rt
reaction
l
gene
transcript
measur
bind
viral
mrna
viral
genom
rna
rel
express
differ
calcul
normal
use
hour
viru
calibr
accord
calcul
develop
pfaffl
calibr
use
normal
amount
mrna
transcript
genom
copi
gener
infect
amount
ad
time
infect
viru
l
gene
transcript
fig
genom
replic
fig
significantli
reduc
infect
compar
wt
infect
p
addit
gene
present
genom
caus
reduct
amount
viral
mrna
transcript
genom
copi
normal
gener
wt
infect
studi
consequ
attenu
detect
replic
three
known
antivir
compound
inhibit
test
three
compound
includ
two
nucleosid
analog
ribavirin
recombin
fusion
protein
sialidas
catalyt
domain
cell
surfaceanchor
sequenc
malakhov
et
al
ec
valu
concentr
compound
inhibit
viru
replic
calcul
compound
wt
virus
mean
standard
deviat
three
replic
found
ribavirin
respect
ngml
ngml
respect
ngml
ngml
respect
viru
significantli
sensit
inhibit
compound
wildtyp
viru
p
support
idea
viru
attenu
determin
earliest
possibl
day
potenti
egfpbas
assay
could
complet
egfp
express
measur
fluoresc
emit
viral
express
egfp
measur
day
infect
cell
variou
moi
viru
egfp
express
rose
dosedepend
manner
begin
day
peak
day
regardless
moi
level
thereaft
fig
even
though
infect
moi
result
greatest
fluoresc
larg
amount
fluoresc
still
detect
three
moi
well
infect
moi
equival
concentr
viru
use
typic
antivir
assay
concentr
viru
use
test
compar
threeday
egfpbas
assay
tradit
nrbase
assay
vybrant
mtt
cell
prolifer
celltiterglo
luminesc
cell
viabil
assay
signaltobackground
ratio
signaltonois
ratio
calcul
tabl
statist
calcul
assess
qualiti
highthroughput
screen
assay
predict
potenti
assay
number
sampl
scale
comput
assay
compar
use
two
differ
fit
tabl
kraybil
zhang
et
al
ultim
higher
valu
mean
assay
robust
use
highthroughput
format
threeday
egfpbas
assay
prove
robust
three
sevenday
assay
nrbase
assay
celltiterglo
luminesc
cell
viabil
assay
vybrant
mtt
cell
prolifer
assay
accord
fit
tabl
egfpbas
nrbase
celltiterglo
luminesc
cell
viabil
assay
consid
good
excel
assay
hand
vybrant
mtt
cell
prolifer
assay
consid
borderlin
excellentmargin
one
tabl
recommend
minimum
level
second
tabl
signaltobackground
ratio
egfp
assay
valu
prove
superior
show
excel
signal
background
signal
separ
nr
assay
valu
result
good
separ
wherea
celltiterglo
luminesc
valu
vybrant
mtt
assay
valu
result
poor
separ
signal
background
signal
addit
egfp
assay
signaltonois
ratio
prove
superior
three
assay
signaltonois
ratio
nr
celltiterglo
vybrant
mtt
show
excel
signal
background
variabl
separ
investig
practic
use
antivir
screen
assay
panel
antivir
compound
select
shown
antivir
activ
past
screen
data
shown
standard
sevenday
nrbase
assay
threeday
egfpbas
assay
use
viru
stock
done
parallel
use
compound
includ
nucleosid
analog
one
fusion
protein
tabl
select
index
si
valu
consid
activ
si
valu
slightli
activ
moder
activ
highli
activ
compound
si
valu
dictat
antivir
drug
would
evalu
addit
assay
use
threshold
si
valu
threeday
egfpbas
assay
sensit
specif
compar
sevenday
nr
assay
use
sevenday
nr
assay
gold
standard
six
compound
fals
identifi
select
inhibitor
viru
replic
use
viru
antivir
assay
led
specif
six
compound
show
increas
si
valu
threshold
egfp
assay
threshold
nr
assay
six
activ
nr
assay
moder
activ
egfp
assay
addit
four
ribamidin
selenazofurin
consid
slightli
activ
nr
assay
moder
activ
egfp
assay
remain
compound
consid
slightli
activ
nr
assay
highli
activ
egfp
assay
factor
contribut
differ
select
detect
assay
lack
toxic
found
cell
expos
compound
egfp
assay
toxic
drug
determin
concentr
lethal
toxic
cell
present
assay
term
ic
toxic
observ
compound
fals
identifi
select
inhibitor
egfp
assay
ic
valu
four
six
compound
significantli
decreas
sevenday
nr
assay
p
differ
toxic
probabl
due
accumul
toxic
sevenday
incub
period
nr
assay
hand
viru
measur
egfp
fluoresc
assay
result
ec
valu
significantli
lower
p
three
six
drug
compar
nr
assay
result
also
contribut
higher
select
detect
compound
egfp
assay
compar
select
compound
evalu
nr
assay
combin
increas
ic
decreas
ec
undoubtedli
increas
si
six
compound
fals
suggest
evalu
explain
low
specif
egfp
assay
overal
compound
trend
seen
increas
si
valu
detect
egfp
fluoresc
assay
compar
nr
assay
case
increas
si
contribut
either
signific
decreas
ec
signific
increas
ic
combin
scenario
purpos
studi
investig
possibl
substitut
wt
initi
screen
potenti
antivir
compound
first
attenu
either
compar
wt
studi
determin
loss
virul
occur
due
either
assembl
rescu
recombin
clone
addit
egfp
gene
rescu
viru
three
genet
mutat
made
distinguish
wt
although
three
genet
marker
detect
rescu
viru
attenu
recombin
viru
two
marker
resid
untransl
region
antigenom
could
disrupt
regulatori
promot
attenu
hand
addit
egfp
gene
viru
increas
length
viral
genom
ad
seventh
distinct
gene
unit
significantli
attenu
rescu
viru
even
though
attenu
statist
signific
reduct
titer
seen
may
signific
wildtyp
viru
grown
vari
cell
cultur
condit
higher
lower
passag
cell
confluent
less
confluent
cell
variat
media
formul
incub
vari
condit
may
inhibit
acceler
viru
replic
greater
reduct
viru
titer
would
indic
sever
attenu
would
suggest
new
viru
inde
biolog
differ
wildtyp
strain
support
point
cpe
produc
significantli
inhibit
acceler
compar
cpe
produc
wt
throughout
durat
viral
infect
although
decreas
viral
titer
slower
viral
replic
detect
viru
cpe
produc
viru
remain
attenu
attribut
combin
small
increas
genom
length
addit
foreign
gene
contribut
significantli
reduc
viral
genom
replic
mrna
transcript
viral
polymeras
termin
reiniti
transcript
gene
junction
inconsist
result
reduct
downstream
gene
transcript
express
gradient
fashion
cattaneo
et
al
homann
et
al
thu
first
six
viral
gene
np
express
significantli
higher
level
compar
last
l
gene
therefor
insert
egfp
gene
first
viral
gene
posit
result
reduct
mrna
transcript
downstream
viral
gene
due
inconsist
termin
reiniti
viral
polymeras
phenomenon
confirm
transcript
l
gene
reduc
viru
infect
compar
wt
viru
infect
addit
genom
replic
also
reduc
perhap
due
overal
declin
express
necessari
viral
replic
protein
signific
reduct
viral
transcript
could
also
lead
reduct
translat
viral
transcript
overal
less
viral
protein
would
avail
replic
purpos
result
less
effici
viral
replic
thu
less
virion
would
assembl
reduct
viral
protein
genom
rna
strand
result
attenu
viru
furthermor
ribavirin
inhibit
inosin
monophosph
dehydrogenas
orotidin
monophosph
decarboxylas
respect
classifi
nucleosid
analog
may
incorpor
viral
rna
strand
interfer
protein
translat
genom
replic
de
clercq
sidwel
reduc
ec
valu
probabl
relat
reduct
mrna
transcript
genom
replic
therefor
less
compound
need
incorpor
rna
strand
inhibit
viral
express
hand
elimin
host
cell
receptor
need
viral
entri
inhibit
virion
bind
absorpt
malakhov
et
al
reduc
ec
valu
like
due
reduct
viabl
virion
produc
attenu
viru
therefor
less
compound
requir
prevent
virion
attach
consequ
slightli
attenu
viru
possibl
reduc
ec
valu
may
increas
si
valu
threshold
result
fals
posit
mean
compound
may
inhibit
wild
type
viru
much
consequ
accept
initi
screen
highthroughput
assay
fals
posit
compound
would
retest
presenc
wildtyp
viru
true
fals
posit
would
elimin
second
round
screen
potenti
use
recombin
viru
express
report
gene
measur
viral
replic
lead
possibl
detect
viru
earlier
assay
assay
use
dye
enzym
like
nr
vybrant
mtt
celltiterglo
luminesc
measur
health
cell
assay
accur
maximum
differ
signal
background
need
achiev
occur
type
assay
viru
complet
lyse
infect
cell
monolay
cell
membran
becom
nonfunct
length
time
need
reach
point
depend
upon
viru
viru
use
studi
requir
seven
day
achiev
complet
cell
destruct
moi
use
howev
use
assay
measur
viral
express
report
gene
incub
time
limit
report
gene
reach
maxim
accept
signaltobackground
ratio
level
egfp
express
detect
hour
postinfect
reach
peak
three
day
dose
respons
manner
characterist
syncytia
format
viru
might
reason
abund
egfp
express
level
achiev
remain
five
day
maximum
express
level
reach
even
lowest
dose
viru
shown
could
potenti
use
antivir
assay
purpos
studi
chose
use
concentr
viru
equival
concentr
viru
use
typic
antivir
assay
broad
rang
egfp
detect
possibl
length
time
concentr
viru
could
potenti
use
experi
need
defin
paramet
threeday
egfpbas
assay
evalu
use
highthroughput
assay
use
analysi
paramet
good
excel
valu
addit
high
signaltobackground
signaltonois
ratio
take
account
variabl
signal
background
differ
signal
background
thu
virusexpress
egfp
gene
suitabl
type
assay
infect
cell
fluoresc
background
measur
seen
due
autofluoresc
plate
medium
cell
subtract
signal
hand
nr
vybrant
mtt
celltiterglo
luminesc
assay
measur
intact
cell
infect
infect
viru
problemat
viru
lyse
cell
monolay
complet
background
measur
rais
reduc
sensit
valid
assay
exampl
celltiterglo
luminesc
assay
suscept
phenomenon
even
cell
viru
control
complet
lyse
determin
visual
signific
luminesc
measur
compar
nocel
control
data
shown
thu
poor
signaltobackground
signaltonois
ratio
luminesc
assay
threeday
egfp
assay
evalu
panel
known
inhibitor
wt
replic
assay
result
excel
sensit
margin
specif
viru
use
antivir
assay
fluoresc
measur
approxim
equal
number
fals
posit
true
posit
would
pass
initi
round
antivir
drug
screen
howev
concern
second
round
antivir
drug
test
wt
viru
would
use
result
measur
nr
uptak
assay
addit
activ
compound
could
also
evalu
valid
viru
yield
reduct
assay
modifi
plaqu
reduct
assay
barnard
et
al
matrosovich
et
al
thu
true
fals
posit
would
detect
elimin
drug
screen
process
would
concern
sensit
margin
would
mean
fals
neg
compound
would
elimin
test
howev
differ
seen
si
valu
determin
egfpbas
nrbase
assay
due
differ
drug
toxic
measur
three
seven
day
respect
compound
question
seem
less
toxic
day
three
day
seven
impli
toxic
effect
accumul
time
addit
cell
growth
may
slow
lead
appar
cell
growth
inhibit
due
deplet
nutrient
acid
build
medium
seven
day
incub
two
phenomena
probabl
contribut
appar
increas
toxic
measur
ic
valu
sevenday
nr
assay
furthermor
addit
factor
contribut
cell
toxic
accur
assay
detect
cell
toxic
conduct
followup
studi
activ
compound
use
rapidlydivid
cell
incub
day
absenc
viru
measur
nr
uptak
essenc
threeday
egfp
assay
may
accur
compar
sevenday
nr
assay
measur
cell
toxic
develop
egfp
assay
increas
sensit
qualiti
antivir
assay
shorten
durat
significantli
decreas
although
complet
elimin
time
consum
labor
intens
natur
nr
dye
uptak
assay
overal
use
viru
initi
antivir
drug
test
reduc
amount
time
need
obtain
result
may
benefici
test
numer
compound
highthroughput
format
conclus
warrant
replac
wt
viru
viru
initi
antivir
test
final
addit
research
improv
threeday
egfp
assay
might
includ
scalingup
plate
format
develop
nongreen
fluoresc
dye
replac
nr
cell
toxic
measur
egfp
insert
viral
antigenom
first
gene
bp
egfp
pcr
product
insert
natur
drdi
site
locat
n
gene
start
signal
start
codon
revers
primer
use
amplifi
egfp
orf
design
encod
gene
end
gene
start
signal
indic
promot
preced
antigenom
leader
sequenc
trrib
indic
hepat
delta
ribozym
immedi
follow
antigenom
trailer
sequenc
b
sequenc
data
show
three
intent
mutat
recombin
marker
g
destroy
natur
sphi
site
indic
destroy
locat
noncod
region
l
gene
c
g
creation
uniqu
draiii
site
locat
within
trailer
region
c
electrophoresi
pcr
fragment
wt
digest
sphi
infecti
assay
compar
recombin
viru
express
egfp
wildtyp
recombin
virus
singl
step
growth
curv
wt
use
separ
infect
plate
seed
cell
moi
individu
cell
harvest
everi
six
hour
includ
hour
viral
titer
measur
plaqu
assay
growth
curv
significantli
differ
compar
growth
curv
wt
p
growth
curv
significantli
differ
compar
growth
curv
wt
p
b
time
cours
viru
induc
cpe
wt
use
infect
cell
moi
plate
day
includ
day
cell
one
plate
stain
nr
hour
wash
pb
nr
extract
ethanol
citrat
buffer
min
rock
absorb
measur
spectrophotomet
use
nm
wavelength
percent
calcul
base
nr
reduct
infect
cell
compar
uninfect
cell
control
signific
differ
detect
p
rel
express
differ
l
gene
transcript
c
genom
replic
measur
qrtpcr
cell
infect
egfp
express
curv
plate
seed
cell
infect
differ
moi
day
includ
day
cell
monolay
wash
pb
fluoresc
measur
wt
infect
also
done
parallel
fluoresc
detect
data
shown
yaxi
valu
repres
mean
sd
duplic
assay
statist
calcul
assess
qualiti
highthroughput
screen
assay
predict
potenti
assay
number
sampl
scale
antivir
re
author
manuscript
avail
pmc
april
panel
antivir
compound
test
tradit
sevenday
colorimetr
neutral
red
uptak
assay
threeday
egfp
fluoresc
assay
use
viru
